[Hodgkin's disease trials conducted by the European Organization of Research and Treatment of Cancer (EORTC): their impact on the progress of cancerology].
Hodgkin's disease is a rare event that allowed key progress in the field of Oncology. Starting 1964 the EORTC has conducted a series of comprehensive controlled trials of outmost importance from the time of the first cures achieved with extended field radiotherapy until the observation that dose-response relationships could occur both for tumor control and for the incidence of second leukemia, cardiac, and pulmonary toxicities. Each of these steps is depicted in some detail. The contributions of the EORTC include in particular the first demonstration ever of the positive impact of an adjuvant chemotherapy on the freedom from progression and overall survival of a cancer (1964-1972), the identification of prognostic factors usable to adapt the aggressivity of treatment to patient's risks and the role of excess mortality from iatrogenic origin. Directions are indicated to insure a continuous progress to the Oncology field through additional Hodgkin's disease studies.
Carde
P
P
Institut Gustave Roussy (Service de médecine C--Unité Suzanne Axel), Villejuif.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005060:Europe; D006689:Hodgkin Disease / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D016032:Randomized Controlled Trials as Topic
Les essais concernant la maladie de Hodgkin's menés par l'Organisation Européenne de Recherche et de Traitement sur le Cancer (OERTC): leur impact sur les progrès en cancérologie.